Cutaneous hyperpigmentation as a manifestation in acuteon chronic liver failure
Main Article Content
Keywords
Hyperpigmentation, Liver Diseases, Acute-On-Chronic Liver Failure
Abstract
Background: The acquired cutaneous pigmentation represents a little recognized clinical manifestation in liver disorders, both acute and chronic, and can occur in the exacerbation processes of preexisting hepatopathies, as in the context of acuteon chronic liver failure. Several hypotheses about the increase in pigment at skin and mucous membranes have been developed; some try to explain it as a defect in the degradation of melanin with secondary accumulation at tissues; others, on the other hand, describe it as a consequence of the release of fibroblast growth factors like endothelial growth factor and hepatocyte growth factor, which are produced under the stimulation of liver regeneration and cause a melanogenesis stimulation. The aim of this article is to describe pigmentary skin changes in the background of liver diseases.
Clinical case: We described two clinical cases of patients with acuteon chronic liver failure secondary to different clinical scenarios are presented, who have in common the development of acquired pigmentary skin changes.
Conclusion: In hepatopathies, the cutaneous hyperpigmentation is a sign with unknown etiology, so further studies are required to know the accurate pathophysiology. Reporting this finding is useful for physicians, since timely identification can help in the early diagnosis of underlying liver diseases.
References
Lu C-Y, Hsieh M-S, Wei K-C, Ezmerli M, Kuo C-H, Chen W. Gastrointestinal involvement of primary skin diseases. J Eur Acad Dermatol Venereol. 2020;34(12):2766-74. DOI: https:// doi.org/10.1111/jdv.16676.
Liu Q. Role of cytokines in the pathophysiology of acute-on-chronic liver failure. Blood Purif. 2009;28(4):331-41. DOI: https://doi.org/10.1159/000232940.
Satapathy SK, Bernstein D. Dermatologic disorders and the liver. Clin Liver Dis. 2011;15(1):165-82. DOI: https://doi. org/10.1016/j.cld.2010.09.001.
Koulaouzidis A, Bhat S, Moschos J. Skin manifestations of liver diseases. Ann Hepatol. 2007;6(3):181-184. DOI: https:// doi.org/10.1016/S1665-2681(19)31926-X.
Smith KE, Fenske NA. Cutaneous manifestations of alcohol abuse. J Am Acad Dermatol. 2000;43(1):1-18. DOI: https:// doi.org/10.1067/mjd.2000.104512.
Beretta-Piccoli BT, Invernizzi P, Gershwin ME, Mainetti C. Skin manifestations associated with autoimmune liver diseases: a systematic review. Clin Rev Allergy Immunol. 2017;53(3):394- 412. DOI: https://doi.org/10.1007/s12016-017-8649-9.
Dogra S, Jindal R. Cutaneous manifestations of common liver diseases. J Clin Exp Hepatol. 2011;1(3):177-84. DOI: https://doi.org/10.1016/S0973-6883(11)60235-1.
Pozdnyakova ON, Nemchaninova OB, Lykova SG, Reshetnikova TB. Clinical features of «metabolism» diseases of the skin in patients with chronic diffuse liver diseases. Ter Arkh. 2017;89(1):49- 52. DOI: https://doi.org/10.17116/terarkh201789149-52.
Le LC, Chosidow O. Clinical practice. Lichen planus. N Engl J Med. 2012;366(8):723-32. DOI: doi.org/10.1056/ NEJMcp1103641.
Mills PR, Skerrow CJ, MacKie RM. Melanin pigmentation of the skin in primary biliary cirrhosis. J Cutan Pathol. 1981;8(6):404- 10. DOI: https://doi.org/10.1111/j.1600-0560.1981.tb01029.x.
Sarin SK, Monga R, Sandhu BS, Sharma BC, Sakhuja P, Malhotra V. Primary biliary cirrhosis in India. Hepatobiliary & pancreatic diseases international. 2006;5(1):105-9.
Koulentaki M, Ioannidou D, Stefanidou M, Maraki S, Drigiannakis I, Dimoulios P, et al. Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am J Gastroenterol. 2006;101(3):541-6. DOI: https://doi.org/ 10.1111/j.1572-0241.2006.00423.x.
Beretta-Piccoli BT, Guillod C, Marsteller I, Blum R, Mazzucchelli L, Mondino C, et al. Primary biliary cholangitis associated with skin disorders: a case report and review of the literature. Arch Immunol Ther Exp (Warsz). 2017;65(4):299- 309. DOI: https://doi.org/10.1007/s00005-016-0448-0.
Callen JP, Jorizzo JL, Zone JJ, Piette W, Rosenbach MA, Vleugels RA. Dermatological Signs of Systemic Disease EBook. Elsevier Health Sciences; 2016.
Liver EA for the S of the. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145-72. DOI: https://doi. org/10.1016/j.jhep.2017.03.022.
Kaplan MM. Primary biliary cirrhosis. N Engl J Med. 1996;335(21):1570-80. DOI: https://doi.org/10.1056/ NEJM199611213352107.
Kapoor R, Dhatwalia SK, Kumar R, Rani S, Parsad D. Emerging role of dermal compartment in skin pigmentation: comprehensive review. J Eur Acad Dermatol Venereol. 2020;34(12):2757-65. DOI: https://doi.org/10.1111/jdv.16404.
Li P-H, Liu L-H, Chang C-C, Gao R, Leung C-H, Ma D-L, et al. Silencing stem cell factor gene in fibroblasts to regulate paracrine factor productions and enhance c-kit expression in melanocytes on melanogenesis. Int J Mol Sci. 2018;19(5):1475. DOI: https://doi.org/10.3390/ijms19051475.
Cardinali G, Kovacs D, del Giglio M, Cota C, Aspite N, Amantea A, et al. A kindred with familial progressive hyperpigmentation-like disorder: implication of fibroblast-derived growth factors in pigmentation. Eur J Dermatol. 2009;19(5):469-73. DOI: https:/doi.org/10.1684/ejd.2009.0724.
Byun JW, Park IS, Choi GS, Shin J. Role of fibroblast-derived factors in the pathogenesis of melasma. Clin Exp Dermatol. 2016;41(6):601-9. DOI: https://doi.org/10.1111/ced.12874.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.